Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28891561 | 0.77 | F2R (0.41) | ALDH1A1HPGDRAB9ANPC1HTT | |
| SCHEMBL9252328 | 0.75 | CES2 (0.45) | ALDH1A1HPGDRAB9ANPC1HTT | |
| SCHEMBL17868849 | 0.73 | CYP3A4 (0.40) | ALDH1A1KDM4EHPGDRAB9ANPC1 | |
| SCHEMBL8497069 | 0.72 | NPC1 (0.41) | ALDH1A1HPGDRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13369478 | 0.71 | TAAR1 (0.38) | ALDH1A1HPGDRAB9ANPC1HTT | |
| SCHEMBL1812180 | 0.70 | NPC1 (0.39) | ALDH1A1HPGDRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5879283 | 0.69 | KMT2A (0.39) | ALDH1A1HPGDRAB9ANPC1HTT | |
| SCHEMBL3752087 | 0.69 | MAOA (0.50) | ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A | |
| SCHEMBL31583030 | 0.69 | NPC1 (0.41) | ALDH1A1HPGDRAB9ANPC1L3MBTL1 | |
| SCHEMBL3445603 | 0.69 | NPC1 (0.41) | ALDH1A1HPGDRAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | ALDH1A1 257/4885KDM4E 3168/4885HPGD 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.